Detalles de la búsqueda
1.
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Neuropsychopharmacology
; 49(2): 467-475, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875578
2.
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Am J Psychiatry
; 180(9): 676-684, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37132201
3.
Zuranolone for the Treatment of Postpartum Depression.
Am J Psychiatry
; 180(9): 668-675, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37491938
4.
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
J Clin Psychiatry
; 85(1)2023 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38153320
5.
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
JAMA Neurol
; 79(1): 13-21, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807243
6.
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Ann Neurol
; 68(3): 304-10, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20737514
7.
Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia.
Eur J Drug Metab Pharmacokinet
; 46(3): 395-404, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782834
8.
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Neurol Ther
; 10(2): 919-940, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34426940
9.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Lancet Neurol
; 17(5): 405-415, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545067
10.
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
J Neurol Sci
; 341(1-2): 22-7, 2014 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24731783
11.
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
Neurology
; 83(1): 78-86, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24898925
Resultados
1 -
11
de 11
1
Próxima >
>>